CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Dapiglutide, a novel GLP-1/GLP-2 receptor agonist, was associated with body weight reductions of up to 8.3% at 13 weeks for ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with ...

One of the largest theater chains in the US again files for bankruptcy Officials provide update on California fireworks ...

A report from the human resources trade group SHRM, which just released its 2025 Benefits Survey—the most comprehensive ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

This is Prime Therapeutics’ latest research into GLP-1s and the long term impact of taking the medication. In October of last ...